Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Muscular atrophy | D009133 | HP_0003202 | — | 1 | 1 | — | — | — | 1 |
Spinal muscular atrophy | D009134 | EFO_0003823 | G12.1 | 1 | 1 | — | — | — | 1 |
Atrophy | D001284 | — | — | 1 | 1 | — | — | — | 1 |
Huntington disease | D006816 | Orphanet_399 | G10 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | BRANAPLAM |
INN | branaplam |
Description | Branaplam (development codes LMI070 and NVS-SM1) is a pyridazine derivative that is being studied as an experimental drug. It was originally developed by Novartis to treat spinal muscular atrophy (SMA); since 2020 it was being developed to treat Huntington's disease (HD) but the trial ended in 2023 with harmful side effects.
|
Classification | Small molecule |
Drug class | survival motor neurin SMN1 and SMN2 splicing modulators |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC1(C)CC(Oc2ccc(-c3ccc(-c4cn[nH]c4)cc3O)nn2)CC(C)(C)N1 |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4290141 |
ChEBI ID | — |
PubChem CID | 135565042 |
DrugBank | — |
UNII ID | P12R69543A (ChemIDplus, GSRS) |